Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute and Honorary Professor of Medicine at Cardiff University School of Medicine, shared a post on LinkedIn:
“Real-World Outcomes Diverge from KEYNOTE-522 in Early-Stage Triple-Negative Breast Cancer
In this multi-institutional real-world cohort, we observed a lower pCR rate, higher rates of toxicity, frequent emergency health care utilization, and the reporting of rare immune related adverse events (irAEs) at higher frequency than the KEYNOTE-522 regimen. These findings have important implications for clinical management of patients with early-stage TNBC and warrant further validation with real-world data sets.”
Title: Real-World Analysis of Adverse Events in Patients With Triple-Negative Breast Cancer Receiving Therapy per KEYNOTE-522
Authors: Mara Lacy Hofherr, Andrew A. Davis, Spenser January, Farah Raheem, Lauren Lyons, Jerline Hsin, Shawna Kraft and Katherine Clifton
Other articles featuring Kefah Mokbel on OncoDaily.